Zika Virus: Information for States and Territories

At a Glance – Zika in the U.S. (updated 8/16/17*)

U.S. States
Travel-associated Zika virus disease cases reported: 5,142
Locally acquired vector-borne cases reported: 224
Laboratory acquired cases reported: 1
Pregnant Women with Any Lab Evidence of Zika Virus Infection: 2,112
Liveborn infants with birth defectss: 93
Pregnancy losses with birth defects: 8

Of the 5,413 cases (203 in 2017) reported, 47 were sexually transmitted.

U.S. Territories
Total cases reported: 37,012 (554 in 2017)
Travel-associated cases reported:147
Locally acquired cases reported: 36,865 
Pregnant Women with Any Lab Evidence of Zika Virus Infection: 4,418
Liveborn infants with birth defects: 128
Pregnancy losses with birth defects: 7

*Visit CDC.gov for the most up to date information.This webpage contains cumulative provisional data reported to ArboNET since 1/1/2015.


New from ASTHO: Top Questions on Zika: Simple Answers


Zika virus is a mosquito-borne flavivirus transmitted to humans primarily by the Aedes aegypti mosquitoes, the same mosquitoes that transmit dengue, yellow fever, and chikungunya viruses. CDC estimates that 80 percent of Zika cases are asymptomatic. Symptomatic cases usually result in mild illness and symptoms such as acute onset of fever, rash, joint pain, and conjunctivitis. Some evidence suggests severe outcomes such as Guillian-Barre syndrome and microcephaly in infants via maternal-fetal transmission of Zika virus. There is currently no vaccine to prevent or medicine to treat Zika virus. For more information on Zika virus in the United States see CDC's Zika Virus web page: www.cdc.gov/Zika.


ASTHO staff have compiled the following links to selected resources and background materials that were created by state and territorial health departments and national and international sources for use by state health agency leaders. We'll add to these materials periodically.

What's New

FDA Provides New Tools for Development and Proper Evaluation of Tests for Detecting Zika Virus Infection

On August 17, the U.S. Food and Drug Administration (FDA) announced it has made available a panel of human plasma samples to aid in the regulatory evaluation of serological tests to detect recent Zika virus infection. The FDA’s sample panel consists of plasma samples from anonymous individuals infected with Zika, West Nile, or dengue viruses. Although the panel is not for research purposes, diagnostic developers can use these samples to assess whether their tests can help distinguish recent Zika virus infection from infection with West Nile or dengue viruses. For more information, please visit the FDA website.

Aug. 31 | 11 a.m. – 12 p.m. EDT | Webinar on Businesses and Health Security: The Bottom Line on Preparedness

Join experts from the business and health communities and leaders of the National Health Security Preparedness Index for a conversation about how health security issues like disasters and disease epidemics impact the U.S. economy and can influence key business decisions. This highly interactive discussion will highlight how private sector leaders can utilize the latest health security information to support their bottom lines and community preparedness. The webinar will also provide real-life examples of company policies that support a healthy workforce, minimize the impact of unplanned absences, and help businesses quickly resume operations after large-scale emergencies—such as hurricanes, floods, earthquakes, or infectious disease outbreaks. Register here to attend.

Sept. 5 | 1 – 2 p.m. EDT | Webinar on Beyond the Basics: The Impact of Zika Virus on Vision and Hearing

The American Academy of Pediatrics is hosting a webinar series on Zika Virus Syndrome. The purpose of this webinar is to:

  • Describe the vision and hearing findings seen in infants born with Congenital Zika Virus Syndrome (CZVS).
  • Understand the landscape of research in the area the Zika virus’ impact on vision and hearing.
  • Know what guidance for evaluation, treatment, and long term care a pediatrician can use when seeing a patient with possible or confirmed CZVS.
  • You can submit questions ahead of time to DisasterReady@aap.org or live during the Q&A portion of the webinar. 

Registration is required to attend.

Top Questions on Zika: Simple Answers

ASTHO’s Top Questions on Zika: Simple Answers document was updated on August 8. The document reflects updated guidance on laboratory confirmation testing of pregnant women (Questions 205 and 302).

CDC Zika Topic of the Week for August 7-11 is Know Before You Go”

Please share or retweet messages posted on CDC social media channels to make this helpful information available to your followers. Readers can also download the Zika Topic of the Week widget for their websites in English and Spanish